We tested the effects of the combined CCR1 (ligands being CCL2/3/5/7/14/15/16/23/28) and CCR3 (ligands being CCL5/7/8/11/13/15/24/28) antagonist J113863 on AML cell viability and proliferation; viability was investigated by a flow-cytometric assay and proliferation as 3H-thymidine incorporation (8, 9). The gene discussed is CCL5; the disease is acute myeloid leukemia.